nudelman-herceptin
19 September 2023FeaturesBig PharmaTakanori Abe

Regimen patents in Japan: LCM failures and successes

Regimen patenting is part of the lifecycle management (LCM) strategy of originator companies. The following is an overview of LCM failures and successes in regimen patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Big Pharma
18 June 2026   Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.
Big Pharma
15 April 2026   The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.
Big Pharma
23 March 2026   With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?